CCA
KERX

Checchi Capital Advisers’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Checchi Capital Advisers’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-16
Closed – – 1442
2016
Q2 		$0 Hold
16
– – ﹤0.01% 1666
2016
Q1 		$0 Buy
+16
New +$64 ﹤0.01% 1633

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Checchi Capital Advisers's KERX Position: Q3 2016 in Review

Checchi Capital Advisers sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2016, closing a stake of 16 shares.

Checchi Capital Advisers first reported a position in KERX in Q1 2016 and held it in 2 quarters. The position peaked at $0 in Q2 2016. 116 funds tracked by Wall St. Rank hold KERX as of Q3 2016.

  • Checchi Capital Advisers reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Checchi Capital Advisers sold 16 Keryx Biopharmaceuticals Inc shares in Q3 2016.
  • Checchi Capital Advisers first reported a position in Keryx Biopharmaceuticals Inc in Q1 2016 and held it in 2 quarters.
  • Checchi Capital Advisers's Keryx Biopharmaceuticals Inc position peaked at $0 in Q2 2016.
  • 116 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2016.

Based on Checchi Capital Advisers's 13F filing for Q3 2016, filed 10 Nov 2016.